May 09, 2025

Hand Movements Reveal Autism's Kinematic Signature

Machine learning algorithms can distinguish between patients with and without autism by analyzing finger movements during grasping tasks.

Conexiant

May 09, 2025

Sweetie, Stop: The Harm of Elderspeak

Explore how well-meaning but condescending language like “sweetie” and “dearie” can undermine the dignity of older adults.

KFF Health News

May 09, 2025

Self-Harm Risk Rises Prior to and Following Gabapentinoids 

Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.

Conexiant

May 08, 2025

Medical Oddities: Tummy Time for Grown-Ups

This week’s research: tattoos misfire, tea heals, and tummy time makes a comeback.

Conexiant

May 08, 2025

Mindfulness Therapy May Reduce Opioid Craving Signals

Mindfulness training helped normalize brain responses to positive emotion in people with opioid use disorder, reducing their craving and improving emotional regulation.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

Race, Sex Gaps Reshape Hearing Loss Landscape

A new study reveals significant disparities in hearing loss prevalence: 60.7% of White males are affected, compared with 29.2% of Black females.

Conexiant

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant

April 28, 2025

High Dose Vitamin D May Reduce MS Activity

Vitamin D significantly reduced disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis in the D-Lay MS trial.

Conexiant